Composition of Certain Financial Statement Captions (Details) (USD $) In Thousands, unless otherwise specified	Jun. 30, 2013		Dec. 31, 2012
Accounts receivable, net:
Accounts receivable	$ 23,135		$ 21,636
Less: allowance for doubtful accounts	(908)		(474)
Accounts receivable, net	22,227	[1]	21,162	[1]
Inventories, net:
Finished products	15,169		17,963
Work in-process	1,253		688
Raw materials	4,721		4,923
Less: inventory reserve	(1,365)		(1,313)
Inventory, net	19,778	[1]	22,261	[1]
Intangible assets, net:
Technologies	52,796		52,810
Customer relationships	22,839		23,088
Product registrations	9,690		9,637
Tradenames	3,683		3,746
Covenants not to compete	8,660		8,662
Other	1,180		367
Less: accumulated amortization	(19,073)		(14,072)
Intangible assets, net	79,775		84,238
Accrued expenses:
Income taxes payable	2,421		1,614
Deferred revenue	3,903		1,518
Clinical trials	315		50
Professional fees	933		675
Employee benefits	3,972		3,319
Deferred acquisition payments, net of discount	5,432		6,172
Contingent consideration	5,298		5,126
Interest payable related to the Notes	2,275		0
Other	6,496		6,182
Accrued expenses	31,045		24,656
Other long-term liabilities:
Deferred acquisition payments, net of discount	3,983		3,931
Mortgages and other debts payable	3,636		5,150
Deferred tax liabilities	7,185		9,777
Other, including deferred revenue	2,191		380
Other long-term liabilities	80,603	[1]	34,168	[1]
Cytochroma [Member]
Other long-term liabilities:
Contingent consideration	49,784		0
Farmadiet [Member]
Other long-term liabilities:
Contingent consideration	529		532
OPKO Diagnostics [Member]
Other long-term liabilities:
Contingent consideration	12,746		11,310
FineTech [Member]
Other long-term liabilities:
Contingent consideration	0		2,578
CURNA [Member]
Other long-term liabilities:
Contingent consideration	$ 549		$ 510

[1] As of June 30, 2013 and December 31, 2012, total assets include $6.0 million and $5.6 million, respectively, and total liabilities include $7.8 million and $5.5 million, respectively related to SciVac Ltd ("SciVac"), previously known as SciGen (I.L.) Ltd, a consolidated variable interest entity. SciVac’s consolidated assets are owned by SciVac and SciVac’s consolidated liabilities are those as to which there is no recourse against us. Refer to Note 5.